Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Income from Continuing Operations (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Income from Continuing Operations for 12 consecutive years, with 14229000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 348.06% year-over-year to 14229000.0, compared with a TTM value of 28017000.0 through Sep 2025, up 102.57%, and an annual FY2024 reading of 31869000.0, up 5700.88% over the prior year.
  • Income from Continuing Operations was 14229000.0 for Q3 2025 at CytomX Therapeutics, down from 154000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 23525000.0 in Q1 2025 and bottomed at 34823000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 8393526.32, with a median of 6533000.0 recorded in 2024.
  • Peak annual rise in Income from Continuing Operations hit 2155.08% in 2024, while the deepest fall reached 501.01% in 2024.
  • Year by year, Income from Continuing Operations stood at 34823000.0 in 2021, then surged by 74.8% to 8776000.0 in 2022, then soared by 109.54% to 837000.0 in 2023, then soared by 2155.08% to 18875000.0 in 2024, then tumbled by 175.39% to 14229000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CTMX at 14229000.0 in Q3 2025, 154000.0 in Q2 2025, and 23525000.0 in Q1 2025.